This company has been marked as potentially delisted and may not be actively trading. XORTX Therapeutics (XRTX) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesShort InterestTrendsBuy This Stock XRTX vs. NERV, BLRX, LPCN, MTEX, SCNX, NAII, BIVI, MRKR, PHIO, and LYRAShould you be buying XORTX Therapeutics stock or one of its competitors? The main competitors of XORTX Therapeutics include Minerva Neurosciences (NERV), BioLineRx (BLRX), Lipocine (LPCN), Mannatech (MTEX), Scienture (SCNX), Natural Alternatives International (NAII), BioVie (BIVI), Marker Therapeutics (MRKR), Phio Pharmaceuticals (PHIO), and Lyra Therapeutics (LYRA). These companies are all part of the "med - drugs" industry. XORTX Therapeutics vs. Its Competitors Minerva Neurosciences BioLineRx Lipocine Mannatech Scienture Natural Alternatives International BioVie Marker Therapeutics Phio Pharmaceuticals Lyra Therapeutics XORTX Therapeutics (NASDAQ:XRTX) and Minerva Neurosciences (NASDAQ:NERV) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability. Do insiders and institutionals believe in XRTX or NERV? 0.2% of XORTX Therapeutics shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 6.9% of XORTX Therapeutics shares are held by company insiders. Comparatively, 8.6% of Minerva Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility and risk, XRTX or NERV? XORTX Therapeutics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500. Comparatively, Minerva Neurosciences has a beta of -0.3, suggesting that its stock price is 130% less volatile than the S&P 500. Do analysts prefer XRTX or NERV? Minerva Neurosciences has a consensus price target of $5.00, suggesting a potential upside of 100.80%. Given Minerva Neurosciences' stronger consensus rating and higher possible upside, analysts plainly believe Minerva Neurosciences is more favorable than XORTX Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Minerva Neurosciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Does the media refer more to XRTX or NERV? In the previous week, XORTX Therapeutics had 5 more articles in the media than Minerva Neurosciences. MarketBeat recorded 5 mentions for XORTX Therapeutics and 0 mentions for Minerva Neurosciences. XORTX Therapeutics' average media sentiment score of 0.00 equaled Minerva Neurosciences'average media sentiment score. Company Overall Sentiment XORTX Therapeutics Neutral Minerva Neurosciences Neutral Is XRTX or NERV more profitable? Minerva Neurosciences' return on equity of -41.35% beat XORTX Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets XORTX TherapeuticsN/A -73.46% -53.04% Minerva Neurosciences N/A -41.35%31.37% Which has stronger valuation and earnings, XRTX or NERV? XORTX Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXORTX TherapeuticsN/AN/A-$3.31M-$1.35-0.81Minerva NeurosciencesN/AN/A$1.44M$1.481.68 SummaryMinerva Neurosciences beats XORTX Therapeutics on 9 of the 11 factors compared between the two stocks. Get XORTX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for XRTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XRTX vs. The Competition Export to ExcelMetricXORTX TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.73M$2.64B$6.09B$10.49BDividend YieldN/A57.79%5.73%4.81%P/E Ratio-2.0422.9984.5227.09Price / SalesN/A552.78568.62202.80Price / CashN/A168.7137.1661.22Price / Book1.255.3212.246.52Net Income-$3.31M$33.06M$3.32B$276.75M XORTX Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XRTXXORTX Therapeutics0.1084 of 5 stars$1.10+29.4%N/A-53.3%$5.73MN/A-2.04N/ANews CoverageAnalyst ForecastShort Interest ↑Gap UpHigh Trading VolumeNERVMinerva Neurosciences2.7987 of 5 stars$2.53-0.4%$5.00+97.6%-5.0%$17.69MN/A1.719Gap DownBLRXBioLineRx1.6688 of 5 stars$4.02-0.1%$26.00+547.6%-79.8%$17.47M$17.25M-0.4640LPCNLipocine1.9249 of 5 stars$3.12-3.0%$8.00+156.8%-40.1%$17.01M$4.21M-3.6110MTEXMannatech0.1761 of 5 stars$8.84-9.2%N/A+12.1%$16.80M$117.87M-4.33250Gap DownSCNXScienture0.7293 of 5 stars$0.73+0.5%N/A-92.2%$16.80M$140K0.00N/ANews CoverageShort Interest ↑Gap DownNAIINatural Alternatives International1.5648 of 5 stars$2.71+2.0%N/A-44.0%$16.76M$129.86M-1.20290Short Interest ↓Gap UpBIVIBioVie0.5332 of 5 stars$1.96-2.0%N/A-82.9%$14.77MN/A-0.0210MRKRMarker Therapeutics3.6906 of 5 stars$1.04-2.4%$13.17+1,172.1%-68.6%$13.39M$6.59M-0.7660PHIOPhio Pharmaceuticals1.4624 of 5 stars$2.21-0.5%$14.00+533.5%-20.4%$12.66MN/A-0.6810LYRALyra Therapeutics2.7979 of 5 stars$7.65+3.8%$100.00+1,207.4%-40.7%$12.46M$1.53M-0.2650Gap Up Related Companies and Tools Related Companies NERV Alternatives BLRX Alternatives LPCN Alternatives MTEX Alternatives SCNX Alternatives NAII Alternatives BIVI Alternatives MRKR Alternatives PHIO Alternatives LYRA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XRTX) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersHoly ****... This could actually MAGAA new document circulating from Washington is stirring major controversy — one that some say could redefine Am...StocksToTrade | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XORTX Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share XORTX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
